BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會


Zih Yuan Tang Biotechnology Co., LTD


Company Info

Name /Zih Yuan Tang Biotechnology Co., LTD (資元堂生物科技股份有限公司)

Address /7F., No. 15, Ln. 132, Sec. 2nd, Keelung Rd., Daan Distr., Taipei City 106051, Taiwan

Website /


Name /Dr. Lung-JR Lin (Ph.D.)

Title /Executive Director

Email /

Telephone /(Work) +886-2-2378-0588

Fax /

Mobile /+886-988-480-635

Company Type


About the Company

ZIH YUAN TANG Biotech is gathered by pharmacologists and experts of Chinese medicine and founded since 2005. We collaborate with academies in Taiwan and focus on small molecules for cancer and metabolic diseases from Chinese medicinal herbs. Several special small molecules have been identified and patented for therapeutic use in diabetes, diabetic wound healing and diabetic retinopathy at recent years. We are seeking for financial supporting or collaboration with any other investments and pharmaceutical companies in development of these principles as therapeutic medicines.

Brief Description of main products or services

Diabetic retinopathy is one of diabetic microvascular complications, and differential non-proliferation (early) and proliferation (lately) stages. All known therapies are focused on proliferation stage, that angiogenesis is the major syndrome and cured by anti-angiogenesis drugs. However, irreversible side effects of anti-angiogenesis are argued. Non-proliferation stage is different mechanism from proliferation stage and more ideal time to cure than proliferation, but anti-angiogenesis drugs are less effective. Moreover, regular therapies of diabetic retinopathy by eye-ball injection make patients fear to defy.

The small molecular drug GYT-088 from Chinese medicinal herb is the newest solution for diabetic retinopathy. Diabetic monkey and rodent models are indicated that GYT-088 work as indirectly anti-angiogenesis at non-proliferation stage by oral treatment. Compliment toxicology and pharmacokinetics, GYT-088 is showed high safety and wild treatment. GYT-088 to oral-treat at non-proliferation stage performs strongly market potentials.

Market of diabetic retinopathy is growing 6% per year up and predicted over US$ 9.3 billion in 2024 around the world. There are no drugs for non-proliferation stage to compete with GYT-088 until now, so that it will lead and fully capture all of diabetic retinopathy market. We are looking for financial or collaboration with investors or pharmaceutical companies.

Contact Person

Name /Dr. Lung-JR Lin (Ph.D.)

Email /

Phone /(Work) +886-2-2378-0588